Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29276246 | 0.86 | CSF1R (0.33) | CSF1R | |
| SCHEMBL29276011 | 0.86 | — | — | |
| SCHEMBL31089198 | 0.86 | LPL (0.33) | — | |
| SCHEMBL22655029 | 0.86 | HIF1A (0.32) | CSF1RHIF1A | |
| SCHEMBL30802058 | 0.85 | CSF1R (0.35) | CSF1R | |
| SCHEMBL25403307 | 0.83 | LIPE (0.31) | — | |
| SCHEMBL30994282 | 0.82 | — | — | |
| SCHEMBL30994168 | 0.82 | AAK1 (0.30) | — | |
| SCHEMBL30973498 | 0.82 | CSF1R (0.32) | CSF1R | |
| SCHEMBL30994384 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656635-A1 | SUBSTITUTED BENZENE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2025-12-03 | — | — | EP | disclosed |
| EP-4568975-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024157953-A1 | SUBSTITUTED BENZENE COMPOUND | 第一三共株式会社 | 2024-08-02 | — | — | WO | disclosed |
| WO-2024033845-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-15 | — | — | WO | disclosed |
| CN-116969920-A | Fused pyridazine derivative, preparation method and medical application thereof | 上海辉启生物医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230295113-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295113-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | CSF1R 1181/4885HIF1A 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.